galantamine hydrobromide

Product NDC: 10147-0892
Requested package NDC: 10147-0892-3
11-digit product format: 101470892
Labeler code: 10147
Product ID: 10147-0892_18d1b4cd-7462-4baa-a561-14bf740d22ee
Type: HUMAN PRESCRIPTION DRUG
Nonproprietary name: galantamine hydrobromide
Dosage form: CAPSULE, EXTENDED RELEASE
Route: ORAL
Labeler: Patriot Pharmaceuticals, LLC
Application: NDA021615
Marketing category: NDA
Marketing start: 2004-12-22
Marketing end: 0000-00-00
Substance: GALANTAMINE HYDROBROMIDE
Active strength: 16 mg/1
Pharmacologic classes: Cholinesterase Inhibitor [EPC], Cholinesterase Inhibitors [MoA]
NDC exclude flag: No
Listing certified through: 2023-12-31
Current FDA listing: Historical FDA.report record

NDC auxiliary status#

These records are reproduced from FDA’s unfinished, excluded, and compounder listings. They describe what appeared in the source files; a missing record does not establish a regulatory status. View all current auxiliary records, including entries without an NDC. · View the auxiliary file history.

Current NDC status page 1 of 1 · 1 matching rows.

Dataset, Scope, Product NDC table
Dataset	Scope	Product NDC	Package NDC	Code	Status	Reporting period	Source date
excluded package	package	10147-0892	10147-0892-3	D	Discontinued by firm		2026-08-07

Observed NDC auxiliary status history#

This history shows the information present in each captured FDA auxiliary file. It is not a continuous regulatory timeline, and a missing record does not establish a status.

Historic NDC status page 1 of 1 · 12 matching rows.

View current auxiliary records. · View the auxiliary file history.

Captured / source date, Snapshot, Source SHA-256 table
Captured / source date	Snapshot	Source SHA-256
2025-12-14 17:58 UTC · source 2025-12-05	`d630ba8d3edf…`	`732f749b63fb…`
2025-08-27 00:01 UTC · source 2025-08-26	`f5e01cc5f278…`	`a2eaf40c39c3…`
2025-04-01 02:39 UTC · source 2025-03-31	`2ef7874e63bc…`	`57b86245f4fa…`
2025-03-28 20:22 UTC · source 2025-03-28	`a1b67e2a42f9…`	`c4cf2c586c0d…`
2025-03-22 03:12 UTC · source 2025-03-21	`cfe11265f3b6…`	`090c488252e2…`
2025-03-10 12:48 UTC · source 2025-03-10	`cdf11ea48f46…`	`ba0047e9e063…`
2025-02-02 03:52 UTC · source 2025-01-31	`302b2466d912…`	`e7b80fea0513…`
2025-01-20 13:05 UTC · source 2025-01-20	`ed331223b511…`	`672a5bd82f5f…`
2025-01-11 03:41 UTC · source 2025-01-10	`0efc9e666f02…`	`f202fb6c5f17…`
2024-11-09 02:27 UTC · source 2024-11-08	`ad56d346431e…`	`cc804d4bbf1e…`
2024-10-04 04:10 UTC · source 2024-10-03	`367a005e9d99…`	`383a685ebd0f…`
2024-07-10 04:00 UTC · source 2024-07-09	`557ba5c1ecfa…`	`9c80585c8c6e…`

Source provenance: Browse the complete Orange Book source catalog · source snapshot 1.

Orange Book products#

Current product rows page 1 of 1 · 3 matching rows.

Application-product, Trade name, Ingredient table
Application-product	Trade name	Ingredient	Strength	Dosage form / route	RLD / RS	Approval date
N021615-001	RAZADYNE ER	GALANTAMINE HYDROBROMIDE	EQ 8MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01
N021615-002	RAZADYNE ER	GALANTAMINE HYDROBROMIDE	EQ 16MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01
N021615-003	RAZADYNE ER	GALANTAMINE HYDROBROMIDE	EQ 24MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 4 · 123 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Trade name	Strength	Dosage form / route	RLD / RS	Approval date	Source SHA-256
2026-02-19 14:30 UTC	2026-02	N021615-001	RAZADYNE ER	EQ 8MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N021615-002	RAZADYNE ER	EQ 16MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	N021615-003	RAZADYNE ER	EQ 24MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N021615-001	RAZADYNE ER	EQ 8MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N021615-002	RAZADYNE ER	EQ 16MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	N021615-003	RAZADYNE ER	EQ 24MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	N021615-001	RAZADYNE ER	EQ 8MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N021615-002	RAZADYNE ER	EQ 16MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	N021615-003	RAZADYNE ER	EQ 24MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`6a471c1ec25d…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N021615-001	RAZADYNE ER	EQ 8MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N021615-002	RAZADYNE ER	EQ 16MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	N021615-003	RAZADYNE ER	EQ 24MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`fd3edfee7708…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N021615-001	RAZADYNE ER	EQ 8MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N021615-002	RAZADYNE ER	EQ 16MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`b8a1b40f171c…`
2025-02-26 10:13 UTC · 3 captures of this ZIP	2025-02	N021615-003	RAZADYNE ER	EQ 24MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`b8a1b40f171c…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N021615-001	RAZADYNE ER	EQ 8MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N021615-002	RAZADYNE ER	EQ 16MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`03ed91905a0d…`
2025-01-19 17:59 UTC · 7 captures of this ZIP	2025-01	N021615-003	RAZADYNE ER	EQ 24MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`03ed91905a0d…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N021615-001	RAZADYNE ER	EQ 8MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N021615-002	RAZADYNE ER	EQ 16MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`2680178bc6a6…`
2024-12-13 21:23 UTC · 2 captures of this ZIP	2024-12	N021615-003	RAZADYNE ER	EQ 24MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`2680178bc6a6…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N021615-001	RAZADYNE ER	EQ 8MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`5bbf6a4d5a75…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N021615-002	RAZADYNE ER	EQ 16MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`5bbf6a4d5a75…`
2024-09-14 05:58 UTC · 2 captures of this ZIP	2024-09	N021615-003	RAZADYNE ER	EQ 24MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`5bbf6a4d5a75…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N021615-001	RAZADYNE ER	EQ 8MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`d8e5a09893c0…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N021615-002	RAZADYNE ER	EQ 16MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`d8e5a09893c0…`
2024-11-08 22:44 UTC · 3 captures of this ZIP	2024-11	N021615-003	RAZADYNE ER	EQ 24MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`d8e5a09893c0…`
2024-10-29 15:01 UTC	2024-10	N021615-001	RAZADYNE ER	EQ 8MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`d06236e962d9…`
2024-10-29 15:01 UTC	2024-10	N021615-002	RAZADYNE ER	EQ 16MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`d06236e962d9…`
2024-10-29 15:01 UTC	2024-10	N021615-003	RAZADYNE ER	EQ 24MG BASE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`d06236e962d9…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	N021615-001	RAZADYNE ER	EQ 8MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`79d66fd596c7…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	N021615-002	RAZADYNE ER	EQ 16MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`79d66fd596c7…`
2024-08-13 05:28 UTC · 3 captures of this ZIP	2024-08	N021615-003	RAZADYNE ER	EQ 24MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`79d66fd596c7…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	N021615-001	RAZADYNE ER	EQ 8MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`301d65b070ca…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	N021615-002	RAZADYNE ER	EQ 16MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`301d65b070ca…`
2024-07-13 05:37 UTC · 2 captures of this ZIP	2024-07	N021615-003	RAZADYNE ER	EQ 24MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`301d65b070ca…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	N021615-001	RAZADYNE ER	EQ 8MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`1e350fbaab3a…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	N021615-002	RAZADYNE ER	EQ 16MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`1e350fbaab3a…`
2024-06-18 03:08 UTC · 5 captures of this ZIP	2024-06	N021615-003	RAZADYNE ER	EQ 24MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`1e350fbaab3a…`
2024-05-31 18:47 UTC	2024-05	N021615-001	RAZADYNE ER	EQ 8MG BASE	CAPSULE, EXTENDED RELEASE / ORAL	RLD	2005-04-01	`8072bd15b7f6…`

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 63 observed states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	TE code	Order	Source SHA-256
2022-06-29 02:47 UTC · 2 captures of this ZIP	2022-06	N021615-001	AB	1	`5c6f7cd8ea54…`
2022-06-29 02:47 UTC · 2 captures of this ZIP	2022-06	N021615-002	AB	1	`5c6f7cd8ea54…`
2022-06-29 02:47 UTC · 2 captures of this ZIP	2022-06	N021615-003	AB	1	`5c6f7cd8ea54…`
2022-04-08 23:34 UTC	2022-04	N021615-001	AB	1	`5d02ea3f76ae…`
2022-04-08 23:34 UTC	2022-04	N021615-002	AB	1	`5d02ea3f76ae…`
2022-04-08 23:34 UTC	2022-04	N021615-003	AB	1	`5d02ea3f76ae…`
2022-04-04 05:41 UTC	2022-04	N021615-001	AB	1	`4b0b4de00fa7…`
2022-04-04 05:41 UTC	2022-04	N021615-002	AB	1	`4b0b4de00fa7…`
2022-04-04 05:41 UTC	2022-04	N021615-003	AB	1	`4b0b4de00fa7…`
2019-12-13 00:20 UTC	2019-12	N021615-001	AB	1	`74a2ff9319b5…`
2019-12-13 00:20 UTC	2019-12	N021615-002	AB	1	`74a2ff9319b5…`
2019-12-13 00:20 UTC	2019-12	N021615-003	AB	1	`74a2ff9319b5…`
2022-03-09 01:35 UTC	2022-03	N021615-001	AB	1	`bb7c543d1eb4…`
2022-03-09 01:35 UTC	2022-03	N021615-002	AB	1	`bb7c543d1eb4…`
2022-03-09 01:35 UTC	2022-03	N021615-003	AB	1	`bb7c543d1eb4…`
2021-12-28 21:50 UTC	2021-12	N021615-001	AB	1	`782e0a99824c…`
2021-12-28 21:50 UTC	2021-12	N021615-002	AB	1	`782e0a99824c…`
2021-12-28 21:50 UTC	2021-12	N021615-003	AB	1	`782e0a99824c…`
2021-05-05 16:15 UTC · 3 captures of this ZIP	2021-05	N021615-001	AB	1	`87673890dc5c…`
2021-05-05 16:15 UTC · 3 captures of this ZIP	2021-05	N021615-002	AB	1	`87673890dc5c…`
2021-05-05 16:15 UTC · 3 captures of this ZIP	2021-05	N021615-003	AB	1	`87673890dc5c…`
2021-03-12 10:30 UTC	2021-03	N021615-001	AB	1	`5aa47cf7b7d7…`
2021-03-12 10:30 UTC	2021-03	N021615-002	AB	1	`5aa47cf7b7d7…`
2021-03-12 10:30 UTC	2021-03	N021615-003	AB	1	`5aa47cf7b7d7…`
2020-12-22 03:56 UTC	2020-12	N021615-001	AB	1	`8869cabd3fbd…`
2020-12-22 03:56 UTC	2020-12	N021615-002	AB	1	`8869cabd3fbd…`
2020-12-22 03:56 UTC	2020-12	N021615-003	AB	1	`8869cabd3fbd…`
2020-11-12 02:37 UTC	2020-11	N021615-001	AB	1	`c0c555d07b60…`
2020-11-12 02:37 UTC	2020-11	N021615-002	AB	1	`c0c555d07b60…`
2020-11-12 02:37 UTC	2020-11	N021615-003	AB	1	`c0c555d07b60…`
2019-12-14 00:12 UTC	2019-12	N021615-001	AB	1	`3f01610625f2…`
2019-12-14 00:12 UTC	2019-12	N021615-002	AB	1	`3f01610625f2…`
2019-12-14 00:12 UTC	2019-12	N021615-003	AB	1	`3f01610625f2…`
2019-09-15 20:21 UTC	2019-09	N021615-001	AB	1	`b00525d2431f…`
2019-09-15 20:21 UTC	2019-09	N021615-002	AB	1	`b00525d2431f…`
2019-09-15 20:21 UTC	2019-09	N021615-003	AB	1	`b00525d2431f…`
2019-07-19 19:46 UTC	2019-07	N021615-001	AB	1	`ea99ee380514…`
2019-07-19 19:46 UTC	2019-07	N021615-002	AB	1	`ea99ee380514…`
2019-07-19 19:46 UTC	2019-07	N021615-003	AB	1	`ea99ee380514…`
2023-07-15 15:27 UTC · 2 captures of this ZIP	2023-07	N021615-001	AB	1	`a67488948f0b…`

Observed Orange Book patent history#

Captured, Edition, Application-product table
Captured	Edition	Application-product	Patent	Expiration	Coverage / status	Source SHA-256
2019-12-13 00:20 UTC	2019-12	N021615-001	7160559	2019-12-20	Drug product	`74a2ff9319b5…`
2019-12-13 00:20 UTC	2019-12	N021615-002	7160559	2019-12-20	Drug product	`74a2ff9319b5…`
2019-12-13 00:20 UTC	2019-12	N021615-003	7160559	2019-12-20	Drug product	`74a2ff9319b5…`
2019-12-14 00:12 UTC	2019-12	N021615-001	7160559	2019-12-20	Drug product	`3f01610625f2…`
2019-12-14 00:12 UTC	2019-12	N021615-002	7160559	2019-12-20	Drug product	`3f01610625f2…`
2019-12-14 00:12 UTC	2019-12	N021615-003	7160559	2019-12-20	Drug product	`3f01610625f2…`
2019-09-15 20:21 UTC	2019-09	N021615-001	7160559	2019-12-20	Drug product	`b00525d2431f…`
2019-09-15 20:21 UTC	2019-09	N021615-002	7160559	2019-12-20	Drug product	`b00525d2431f…`
2019-09-15 20:21 UTC	2019-09	N021615-003	7160559	2019-12-20	Drug product	`b00525d2431f…`
2019-07-19 19:46 UTC	2019-07	N021615-001	7160559	2019-12-20	Drug product	`ea99ee380514…`
2019-07-19 19:46 UTC	2019-07	N021615-002	7160559	2019-12-20	Drug product	`ea99ee380514…`
2019-07-19 19:46 UTC	2019-07	N021615-003	7160559	2019-12-20	Drug product	`ea99ee380514…`

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDC	Billing unit	Product NDC	DailyMed indexing SPL	SPL version	Effective
10147-0892-3	EA - Each	10147-0892	1998b40b-4f0a-45f7-b777-371cb99ad71b	1	2012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
Ingredient	Type	UNII	DailyMed label	SPL version
galantamine hydrobromide	ACTIVE INGREDIENT	MJ4PTD2VVW	GALANTAMINE HYDROBROMIDE TABLET, FILM COATED GALANTAMINE HYDROBROMIDE CAPSULE, EXTENDED RELEASE [PATRIOT PHARMACEUTICALS, LLC]	5
galantamine	ACTIVE MOIETY	0D3Q044KCA	GALANTAMINE HYDROBROMIDE TABLET, FILM COATED GALANTAMINE HYDROBROMIDE CAPSULE, EXTENDED RELEASE [PATRIOT PHARMACEUTICALS, LLC]	5
aluminum oxide	INACTIVE INGREDIENT	LMI26O6933	GALANTAMINE HYDROBROMIDE TABLET, FILM COATED GALANTAMINE HYDROBROMIDE CAPSULE, EXTENDED RELEASE [PATRIOT PHARMACEUTICALS, LLC]	5
cellulose, microcrystalline	INACTIVE INGREDIENT	OP1R32D61U	GALANTAMINE HYDROBROMIDE TABLET, FILM COATED GALANTAMINE HYDROBROMIDE CAPSULE, EXTENDED RELEASE [PATRIOT PHARMACEUTICALS, LLC]	5
crospovidone	INACTIVE INGREDIENT	68401960MK	GALANTAMINE HYDROBROMIDE TABLET, FILM COATED GALANTAMINE HYDROBROMIDE CAPSULE, EXTENDED RELEASE [PATRIOT PHARMACEUTICALS, LLC]	5
D&C Yellow No. 10	INACTIVE INGREDIENT	35SW5USQ3G	GALANTAMINE HYDROBROMIDE TABLET, FILM COATED GALANTAMINE HYDROBROMIDE CAPSULE, EXTENDED RELEASE [PATRIOT PHARMACEUTICALS, LLC]	5
diethyl phthalate	INACTIVE INGREDIENT	UF064M00AF	GALANTAMINE HYDROBROMIDE TABLET, FILM COATED GALANTAMINE HYDROBROMIDE CAPSULE, EXTENDED RELEASE [PATRIOT PHARMACEUTICALS, LLC]	5
ethylcelluloses	INACTIVE INGREDIENT	7Z8S9VYZ4B	GALANTAMINE HYDROBROMIDE TABLET, FILM COATED GALANTAMINE HYDROBROMIDE CAPSULE, EXTENDED RELEASE [PATRIOT PHARMACEUTICALS, LLC]	5
ferric oxide red	INACTIVE INGREDIENT	1K09F3G675	GALANTAMINE HYDROBROMIDE TABLET, FILM COATED GALANTAMINE HYDROBROMIDE CAPSULE, EXTENDED RELEASE [PATRIOT PHARMACEUTICALS, LLC]	5
ferric oxide yellow	INACTIVE INGREDIENT	EX438O2MRT	GALANTAMINE HYDROBROMIDE TABLET, FILM COATED GALANTAMINE HYDROBROMIDE CAPSULE, EXTENDED RELEASE [PATRIOT PHARMACEUTICALS, LLC]	5
gelatin	INACTIVE INGREDIENT	2G86QN327L	GALANTAMINE HYDROBROMIDE TABLET, FILM COATED GALANTAMINE HYDROBROMIDE CAPSULE, EXTENDED RELEASE [PATRIOT PHARMACEUTICALS, LLC]	5
hypromelloses	INACTIVE INGREDIENT	3NXW29V3WO	GALANTAMINE HYDROBROMIDE TABLET, FILM COATED GALANTAMINE HYDROBROMIDE CAPSULE, EXTENDED RELEASE [PATRIOT PHARMACEUTICALS, LLC]	5
lactose monohydrate	INACTIVE INGREDIENT	EWQ57Q8I5X	GALANTAMINE HYDROBROMIDE TABLET, FILM COATED GALANTAMINE HYDROBROMIDE CAPSULE, EXTENDED RELEASE [PATRIOT PHARMACEUTICALS, LLC]	5
magnesium stearate	INACTIVE INGREDIENT	70097M6I30	GALANTAMINE HYDROBROMIDE TABLET, FILM COATED GALANTAMINE HYDROBROMIDE CAPSULE, EXTENDED RELEASE [PATRIOT PHARMACEUTICALS, LLC]	5
polyethylene glycols	INACTIVE INGREDIENT	3WJQ0SDW1A	GALANTAMINE HYDROBROMIDE TABLET, FILM COATED GALANTAMINE HYDROBROMIDE CAPSULE, EXTENDED RELEASE [PATRIOT PHARMACEUTICALS, LLC]	5
silicon dioxide	INACTIVE INGREDIENT	ETJ7Z6XBU4	GALANTAMINE HYDROBROMIDE TABLET, FILM COATED GALANTAMINE HYDROBROMIDE CAPSULE, EXTENDED RELEASE [PATRIOT PHARMACEUTICALS, LLC]	5
talc	INACTIVE INGREDIENT	7SEV7J4R1U	GALANTAMINE HYDROBROMIDE TABLET, FILM COATED GALANTAMINE HYDROBROMIDE CAPSULE, EXTENDED RELEASE [PATRIOT PHARMACEUTICALS, LLC]	5
titanium dioxide	INACTIVE INGREDIENT	15FIX9V2JP	GALANTAMINE HYDROBROMIDE TABLET, FILM COATED GALANTAMINE HYDROBROMIDE CAPSULE, EXTENDED RELEASE [PATRIOT PHARMACEUTICALS, LLC]	5

UNII, Preferred term, Registry number table
UNII	Preferred term	Registry number	Matched term
MJ4PTD2VVW	GALANTAMINE HYDROBROMIDE	1953-04-4	GALANTAMINE HYDROBROMIDE

Packages#

Package NDC, 11-digit format, Description table
Package NDC	11-digit format	Description	Marketing start	Marketing end	Sample	Exclude flag	Status
10147-0892-3	10147089203	30 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (10147-0892-3)	2004-12-22	0000-00-00	No	No	Current

Title, Manufacturer, Effective date table
Title	Manufacturer	Effective date	Type	Version
galantamine hydrobromide	Patriot Pharmaceuticals, LLC \| Janssen Pharmaceuticals Inc. \| Janssen Pharmaceutica NV \| Janssen Ortho, LLC	2023-01-24	HUMAN PRESCRIPTION DRUG LABEL	21